真实世界经验与临床试验：银屑病治疗评估中的利弊 - Suppr

Suppr

超能文献

Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation.

作者信息

Cinelli Eleonora, Fabbrocini Gabriella, Megna Matteo

机构信息

Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

出版信息

Int J Dermatol. 2022 Mar;61(3):e107-e108. doi: 10.1111/ijd.15644. Epub 2021 May 4.

DOI:10.1111/ijd.15644

PMID:33945151

Abstract

摘要

相似文献

Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation.真实世界经验与临床试验：银屑病治疗评估中的利弊

Int J Dermatol. 2022 Mar;61(3):e107-e108. doi: 10.1111/ijd.15644. Epub 2021 May 4.

Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies.银屑病中的药物相互作用：联合外用银屑病治疗方法的利弊

J Cutan Med Surg. 2002 May-Jun;6(3 Suppl):12-6. doi: 10.1177/12034754020060S304. Epub 2002 Apr 30.

Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.美国患者银屑病严重程度对患者报告的临床症状、健康相关生活质量和工作生产力的影响：来自 Corrona 银屑病登记处的真实世界数据。

BMJ Open. 2019 Apr 20;9(4):e027535. doi: 10.1136/bmjopen-2018-027535.

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).一项多国前瞻性观察性研究，旨在评估在真实世界环境中接受生物制剂治疗的中度至重度斑块状银屑病患者的完全皮肤清除情况（PSO-BIO-REAL）。

J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2566-2573. doi: 10.1111/jdv.16568. Epub 2020 Jun 8.

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.司库奇尤单抗治疗银屑病的美国真实世界疗效：来自科罗纳银屑病登记处的6个月分析

J Dermatolog Treat. 2020 Jun;31(4):333-341. doi: 10.1080/09546634.2019.1603361. Epub 2019 Apr 29.

Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.将熟知的活性成分重新配方应用于寻常性银屑病的局部治疗，可以改善患者的临床疗效。

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22.

Treat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy.银屑病的达标治疗：生物制剂与辅助外用治疗的真实世界经验

J Drugs Dermatol. 2018 Aug 1;17(8):918.

Topical methoxsalen photochemotherapy in the treatment of palmoplantar pustulosis and psoriasis.局部甲氧沙林光化学疗法治疗掌跖脓疱病和银屑病。

Acta Derm Venereol Suppl (Stockh). 1979;59(85):193-8.

Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.司库奇尤单抗（白细胞介素17A拮抗剂）：真实世界临床实践中的12周疗效和安全性结果

J Cutan Med Surg. 2019 Mar/Apr;23(2):174-177. doi: 10.1177/1203475418814229. Epub 2018 Nov 18.

Options and opportunities for clinical management and treatment of psoriasis.银屑病的临床管理和治疗的选择和机会。

Crit Rev Ther Drug Carrier Syst. 2013;30(1):51-90. doi: 10.1615/critrevtherdrugcarriersyst.2013005589.

引用本文的文献

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023.司库奇尤单抗治疗银屑病、银屑病关节炎和中轴型脊柱关节炎的真实世界证据：2022 - 2023年系统文献综述

Adv Ther. 2025 Jul 17. doi: 10.1007/s12325-025-03258-9.

Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020-2023.巴瑞替尼治疗特应性皮炎和斑秃的真实世界证据：2020 - 2023年系统文献综述

Dermatol Ther (Heidelb). 2025 May 16. doi: 10.1007/s13555-025-01425-y.

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.比较 14 种治疗银屑病关节炎药物和 5 种治疗银屑病关节炎类别的早期疗效：来自 PRO-SPIRIT 研究的 3 个月结果。

RMD Open. 2024 Sep 20;10(3):e004318. doi: 10.1136/rmdopen-2024-004318.

Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations.曲罗芦单抗用于特殊人群成人特应性皮炎的治疗

J Asthma Allergy. 2024 Aug 14;17:791-799. doi: 10.2147/JAA.S474411. eCollection 2024.

Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study.古塞库单抗在抗IL-17治疗失败的银屑病患者中的长期疗效和安全性：一项为期两年的真实世界研究。

J Clin Med. 2024 May 3;13(9):2691. doi: 10.3390/jcm13092691.

Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.古塞库单抗在对司库奇尤单抗反应不足的银屑病患者中的真实疗效和安全性：一项为期3年的多中心研究。

J Clin Med. 2024 Apr 26;13(9):2552. doi: 10.3390/jcm13092552.

Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland.司库奇尤单抗治疗中重度银屑病——一项来自波兰的多中心、长期、真实世界研究

J Clin Med. 2023 Feb 20;12(4):1675. doi: 10.3390/jcm12041675.

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.抗白细胞介素 23 生物制剂治疗银屑病：真实世界经验与临床试验数据对比。

Immunol Res. 2023 Jun;71(3):328-355. doi: 10.1007/s12026-022-09356-y. Epub 2023 Jan 4.

Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative.提升银屑病患者的护理标准：泛欧洲多方利益相关者倡议Epicensus的“行动呼吁”

Dermatol Ther (Heidelb). 2023 Jan;13(1):245-268. doi: 10.1007/s13555-022-00846-3. Epub 2022 Dec 9.

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.古塞库单抗治疗中度至重度银屑病的长期疗效和安全性：一项3年真实世界回顾性研究

Psoriasis (Auckl). 2022 Jul 14;12:205-212. doi: 10.2147/PTT.S372262. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验